Literature DB >> 12754327

The neuromuscular junction disorders.

Marguerite Hill1.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12754327      PMCID： PMC1765619          DOI： 10.1136/jnnp.74.suppl_2.ii32

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  9 in total

1.  Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  G S Gronseth; R J Barohn
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

Review 2.  Congenital myasthenic syndromes.

Authors:  Andrew G Engel; Kinji Ohno
Journal:  Adv Neurol       Date:  2002

3.  A treatment algorithm for Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis
Journal:  Ann N Y Acad Sci       Date:  1998-05-13       Impact factor: 5.691

4.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

5.  Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.

Authors:  P Gajdos; S Chevret; B Clair; C Tranchant; C Chastang
Journal:  Ann Neurol       Date:  1997-06       Impact factor: 10.422

6.  Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients.

Authors:  G M Elrington; N M Murray; S G Spiro; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

7.  A clinical therapeutic trial of cyclosporine in myasthenia gravis.

Authors:  R S Tindall; J T Phillips; J A Rollins; L Wells; K Hall
Journal:  Ann N Y Acad Sci       Date:  1993-06-21       Impact factor: 5.691

8.  Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England.

Authors:  N P Robertson; J Deans; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

9.  A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

Authors:  J Palace; J Newsom-Davis; B Lecky
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910
  9 in total
  4 in total

Review 1.  Update on myasthenia gravis.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

Review 2.  Moonlighting nuclear pore proteins: tissue-specific nucleoporin function in health and disease.

Authors:  Ramona Jühlen; Birthe Fahrenkrog
Journal:  Histochem Cell Biol       Date:  2018-10-25       Impact factor: 4.304

3.  Identification and molecular characterization of propionylcholinesterase, a novel pseudocholinesterase in rice.

Authors:  Kosuke Yamamoto; Yoshie S Momonoki
Journal:  Plant Signal Behav       Date:  2021-08-02

4.  New Insights into the Lactate Shuttle: Role of MCT4 in the Modulation of the Exercise Capacity.

Authors:  Sara Bisetto; Megan C Wright; Romana A Nowak; Angelo C Lepore; Tejvir S Khurana; Emanuele Loro; Nancy J Philp
Journal:  iScience       Date:  2019-11-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.